Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 3, 2015, Pages e100-

  Miller, Robert G ^a   Block, Gilbert ^b   Katz, Jonathan S ^a   Barohn, Richard J ^c   Gopalakrishnan, Vidhya ^b   Cudkowicz, Merit ^d   Zhang, Jane R ^e   McGrath, Michael S ^b,e   Ludington, Elizabeth ^f   Appel, Stan H ^g   Azhir, Ari ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b Neuraltus Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Agility Clinical Inc   (United States)

^g HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NP 001; PLACEBO; TROPONIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE REVISED; ANXIETY DISORDER; ARTICLE; BACKACHE; CAUSE OF DEATH; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FALLING; FATIGUE; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE EXTRAVASATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LIMB PAIN; LUNG EMBOLISM; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC DISEASE ASSESSMENT; NOSE OBSTRUCTION; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION;

EID: 84945913544     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000100     Document Type: Article

References (19)

1. Boillée S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006;52:39-59.
2. Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol 2009;4:389-398.
3. Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012;122: 3063-3087.
4. Turner MR, Kiernan MC, Leigh PN, Talbot K. Bio-markers in amyotrophic lateral sclerosis. Lancet Neurol 2009;8:94-109.
5. Liu G, Fiala M, Mizwicki MT, et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neuro-degener Dis 2012;1:60-74.
6. Frakes A, Ferraiuolo L, Haidet-Phillips AM, et al. Microg-lia induce motor neuron death via the classical NF-kB pathway in amyotrophic lateral sclerosis. Neuron 2014; 81:1009-1023.
7. Zhang R, Gascon R, Miller RG, et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis. J Neuroimmunol 2005;159:215-224.
8. Zhang R, Hadlock KG, Do H, et al. Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis. J Neuroimmunol 2011;230:114-123.
9. Zhang R, Miller RG, Gascon R, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis. J Neuroimmunol 2009; 206:121-124.
10. Zhang R, Gascon R, Miller RG, et al. MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis. J Neuroimmunol 2006;179:87-93.
11. Barbeito AG, Mesci P, Boillée S. Motor neuron-immune interactions: the vicious circle of ALS. J Neural Transm 2010;117:981-1000.
12. Miller RG, Zhang R, Block G, et al. NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Frontotem-poral Degener 2014;15:601-609.
13. Giese T, McGrath MS, Stumm S, Schempp H, Elstner E, Meuer S. Differential effects on innate versus adaptive immune responses by WF10. Cell Immunol 2004;229:149-158.
14. McGrath MS, Kahn JO, Herndier BG. Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs 2002;3:365-373.
15. Marcinkiewicz J, Grabowska A, Bereta J, Stelmaszynska T. Taurine choloramine, a product of activated neutrophils, inhibits in vitro the generation of nitric oxide and other macrophage inflammatory mediators. J Leukoc Biol 1995; 58:667-674.
16. Joo K, Lee Y, Choi D, et al. An anti-inflammatory mechanism of taurine conjugated 5-aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibi-tory effect of 5-aminosalicylic acid on IL-1beta-mediated NFkappaB activation. Eur J Pharmacol 2009;618:91-97.
17. Keizman D, Rogowski O, Berliner S, et al. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009;119:383-389.
18. Miller RG, Moore DH, Forshew DA, et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis. Neurology 2011;77:973-979.
19. Italiani P, Carlesi C, Giungato P, et al. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflammation 2014;11:94.